[go: up one dir, main page]

MX2023000085A - Compuestos antiproliferativos y metodos para utilizarlos. - Google Patents

Compuestos antiproliferativos y metodos para utilizarlos.

Info

Publication number
MX2023000085A
MX2023000085A MX2023000085A MX2023000085A MX2023000085A MX 2023000085 A MX2023000085 A MX 2023000085A MX 2023000085 A MX2023000085 A MX 2023000085A MX 2023000085 A MX2023000085 A MX 2023000085A MX 2023000085 A MX2023000085 A MX 2023000085A
Authority
MX
Mexico
Prior art keywords
methods
compounds
antiproliferative compounds
compositions
dioxopiperidin
Prior art date
Application number
MX2023000085A
Other languages
English (en)
Inventor
Mark A Nagy
Rama K Narla
Iii Gerald D Artman
Courtney G Havens
Nanfei Zou
Antonia Lopez-Girona
Brian E Cathers
Joshua Hansen
Xiaoling Lu
Matthew D Correa
Gordon L Bray
Lilly L Wong
Soraya Carrancio
James Carmichael
Timothy S Kercher
Joseph R Piccotti
Daniel W Pierce
Brandon W Whitefield
Hon-Wah Man
Matthew D Alexander
Paula A Tavares-Greco
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2023000085A publication Critical patent/MX2023000085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente se proporciona 4-(4-(4-(((2-(2,6-dioxopiperidin-3-i l)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperazin-1-il)-3-fluoro benzonitrilo,ounenantiómero,unamezcla de enantiómeros, un tautómero, o una sal farmacéuticamente aceptable de este, y métodos para tratar, prevenir o controlar el mieloma múltiple mediante el uso de dichos compuestos. También se proporcionan composiciones farmacéuticas que comprenden los compuestos y métodos de uso de las composiciones.
MX2023000085A 2017-07-10 2020-01-10 Compuestos antiproliferativos y metodos para utilizarlos. MX2023000085A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530778P 2017-07-10 2017-07-10
US201762593185P 2017-11-30 2017-11-30
US201862675581P 2018-05-23 2018-05-23

Publications (1)

Publication Number Publication Date
MX2023000085A true MX2023000085A (es) 2023-02-09

Family

ID=63036419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000085A MX2023000085A (es) 2017-07-10 2020-01-10 Compuestos antiproliferativos y metodos para utilizarlos.

Country Status (28)

Country Link
US (5) US10357489B2 (es)
EP (2) EP3651766B1 (es)
JP (1) JP7258009B2 (es)
KR (1) KR102656934B1 (es)
CN (1) CN110869021B (es)
AU (2) AU2018301335B2 (es)
CA (1) CA3069138A1 (es)
CL (1) CL2020000060A1 (es)
CO (1) CO2020000193A2 (es)
DK (1) DK3651766T3 (es)
EC (1) ECSP20001149A (es)
ES (1) ES2992913T3 (es)
FI (1) FI3651766T3 (es)
HR (1) HRP20241553T1 (es)
HU (1) HUE069137T2 (es)
IL (1) IL271889B2 (es)
LT (1) LT3651766T (es)
MX (1) MX2023000085A (es)
PL (1) PL3651766T3 (es)
PT (1) PT3651766T (es)
RS (1) RS66162B1 (es)
SA (1) SA520411007B1 (es)
SG (1) SG11202000143PA (es)
SI (1) SI3651766T1 (es)
SM (1) SMT202400470T1 (es)
TW (2) TWI830576B (es)
WO (1) WO2019014100A1 (es)
ZA (1) ZA202000157B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000143PA (en) * 2017-07-10 2020-02-27 Celgene Corp Antiproliferative compounds and methods of use thereof
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
US11358952B2 (en) 2018-04-23 2022-06-14 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
WO2019226770A1 (en) * 2018-05-23 2019-11-28 Celgene Corporation Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
SG11202011545YA (en) * 2018-05-23 2020-12-30 Celgene Corp Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
US12263190B2 (en) 2018-11-08 2025-04-01 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
CN113597301A (zh) * 2019-01-09 2021-11-02 细胞基因公司 包含(s)-4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的药物组合物以及使用它的方法
EA202191903A1 (ru) * 2019-01-09 2021-11-12 Селджин Корпорейшн Антипролиферативные соединения и вторые активные агенты для комбинированного применения
BR112021013435A2 (pt) * 2019-01-09 2021-10-19 Celgene Corporation Formas sólidas que compreendem (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila e sais do mesmo, e composições que compreendem e métodos de uso do mesmo
BR112021019669A2 (pt) 2019-04-12 2021-12-07 C4 Therapeutics Inc Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
HRP20231487T1 (hr) 2019-10-21 2024-03-01 Celgene Corporation Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona
WO2021105335A1 (en) 2019-11-27 2021-06-03 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
AU2020392427B2 (en) 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
CN115038694A (zh) 2020-01-20 2022-09-09 康朴生物医药技术（上海）有限公司 一种异吲哚啉衍生物、其药物组合物及应用
EP4135691A1 (en) * 2020-04-17 2023-02-22 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x4 and related products and methods
US20230165872A1 (en) * 2020-04-28 2023-06-01 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
CN115803027A (zh) * 2020-04-30 2023-03-14 百时美施贵宝公司 治疗细胞因子相关的不良事件的方法
IL299293A (en) 2020-06-25 2023-02-01 Celgene Corp Cancer treatment methods with combined treatments
CN113896711A (zh) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
RS66027B1 (sr) 2020-07-07 2024-11-29 Celgene Corp Farmaceutske kompozicije koje sadrže (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il)oksi)m etil)benzil)piperazin-1-il)-3-fluorbenzonitril i metode njihove upotrebe
CN115916768B (zh) * 2020-07-20 2024-12-24 江苏恒瑞医药股份有限公司 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
CA3186919A1 (en) 2020-08-03 2022-02-10 Sylvain Cottens Low molecular weight protein degraders and their applications
WO2022146151A1 (en) 2020-12-30 2022-07-07 Captor Therapeutics S.A. Novel compounds which bind to cereblon, and methods of use thereof
CN114685429A (zh) * 2020-12-31 2022-07-01 江苏恒瑞医药股份有限公司 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
JP2024520435A (ja) 2021-05-27 2024-05-24 セルジーン コーポレーション 組み合わせ療法を用いて多発性骨髄腫を治療する方法
WO2022255890A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2022255889A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
EP4380582A1 (en) 2021-08-06 2024-06-12 Celgene Corporation Compositions and methods for selective degradation of engineered proteins
CN116023319A (zh) * 2021-10-25 2023-04-28 英格尔医药科技(上海)有限公司 制备布瓦西坦的方法
CN118510766A (zh) * 2022-01-19 2024-08-16 江苏恒瑞医药股份有限公司 一种含硫异吲哚啉类衍生物的晶型
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000427A1 (en) 1977-07-09 1979-01-24 LUCAS INDUSTRIES public limited company Road vehicle electrical systems
DE2848746A1 (de) 1978-11-10 1980-05-22 Wolfgang Arheiliger Dichtung fuer eine schwellenlose tuere mit drehfluegel
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
WO2000034437A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20060074103A1 (en) 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
RU2396265C2 (ru) 2006-02-17 2010-08-10 Ф. Хоффманн-Ля Рош Аг Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3
WO2008091670A2 (en) 2007-01-24 2008-07-31 Polyera Corporation Organic semiconductor materials and precursors thereof
CN103641814A (zh) 2007-03-20 2014-03-19 细胞基因公司 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
WO2010057087A1 (en) 2008-11-17 2010-05-20 Plextronics, Inc. Organic photovoltaic devices comprising substituted endohedral metallofullerenes
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CA2744563A1 (en) 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
RS56232B1 (sr) * 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
AU2011302124B2 (en) 2010-09-14 2016-03-17 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
JP5728921B2 (ja) 2010-12-10 2015-06-03 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
EA029485B1 (ru) * 2012-08-09 2018-04-30 Селджин Корпорейшн Способы лечения рака, выбранного из лимфомы, лейкоза, миеломы, глиобластомы, рака ободочной и прямой кишки и печеночно-клеточной карциномы, с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
ES2814952T3 (es) 2012-09-04 2021-03-29 Celgene Corp Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20220153684A (ko) 2013-08-22 2022-11-18 반다 파마슈티칼즈, 인코퍼레이티드. 다발성 골수종 치료
EP3172185B1 (en) 2014-07-25 2020-03-04 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
WO2016019386A1 (en) 2014-08-01 2016-02-04 Green Revolution Cooling, Inc. Controller for oil-cooled rack with multiple modes of operation
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
CN107690431A (zh) 2015-07-08 2018-02-13 豪夫迈·罗氏有限公司 作为RORc调节剂的芳基磺内酰胺衍生物
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
EP3445452A4 (en) 2016-04-21 2019-10-30 BioVentures, LLC COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF
US20190054097A1 (en) 2016-04-21 2019-02-21 Bioventures, Llc Compositions targeting senescent cells and the uses thereof
CA3035105C (en) 2016-08-30 2023-09-12 Dow Global Technologies Llc Method of attenuating concentration of acrolein
JP2019530707A (ja) 2016-10-10 2019-10-24 セレラント セラピューティクス インコーポレイテッド イソキノリジノベンゾジアゼピン（ｉｑｂ）−１（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール（ｃｂｉ）二量体
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP4092049A1 (en) 2016-10-20 2022-11-23 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
EP3551185A4 (en) 2016-12-08 2021-07-14 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
SG11202000143PA (en) * 2017-07-10 2020-02-27 Celgene Corp Antiproliferative compounds and methods of use thereof
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
WO2019114770A1 (zh) 2017-12-13 2019-06-20 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
SG11202011545YA (en) * 2018-05-23 2020-12-30 Celgene Corp Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
CN108690020A (zh) 2018-07-04 2018-10-23 清华大学 一种靶向降解bet蛋白的化合物及其应用
CN108794453A (zh) 2018-07-05 2018-11-13 清华大学 一种靶向降解fak蛋白的化合物及其应用

Also Published As

Publication number Publication date
JP7258009B2 (ja) 2023-04-14
DK3651766T3 (da) 2024-11-18
HUE069137T2 (hu) 2025-02-28
BR112020000442A2 (pt) 2020-07-21
AU2018301335A1 (en) 2020-01-30
KR20200026980A (ko) 2020-03-11
KR102656934B1 (ko) 2024-04-16
EP4467143A3 (en) 2025-01-29
US20220280505A1 (en) 2022-09-08
PT3651766T (pt) 2024-11-25
SI3651766T1 (sl) 2025-02-28
TWI791552B (zh) 2023-02-11
HRP20241553T1 (hr) 2025-01-17
NZ760649A (en) 2025-02-28
SMT202400470T1 (it) 2025-01-14
EP3651766B1 (en) 2024-09-11
US20190282567A1 (en) 2019-09-19
RS66162B1 (sr) 2024-12-31
CO2020000193A2 (es) 2020-04-24
US10357489B2 (en) 2019-07-23
US20190008852A1 (en) 2019-01-10
IL271889B (en) 2022-11-01
US20200253964A1 (en) 2020-08-13
AU2022287569B2 (en) 2025-02-20
US12029738B2 (en) 2024-07-09
ES2992913T3 (en) 2024-12-19
EP4467143A2 (en) 2024-11-27
TW202319385A (zh) 2023-05-16
SA520411007B1 (ar) 2024-08-18
PL3651766T3 (pl) 2025-03-03
CN110869021B (zh) 2023-06-30
AU2022287569A1 (en) 2023-02-02
FI3651766T3 (fi) 2024-11-18
LT3651766T (lt) 2024-12-10
TWI830576B (zh) 2024-01-21
TW201907923A (zh) 2019-03-01
EP3651766A1 (en) 2020-05-20
US10675281B2 (en) 2020-06-09
JP2020526534A (ja) 2020-08-31
US20240207255A1 (en) 2024-06-27
CA3069138A1 (en) 2019-01-17
IL271889B2 (en) 2023-03-01
CN110869021A (zh) 2020-03-06
SG11202000143PA (en) 2020-02-27
ECSP20001149A (es) 2020-02-28
WO2019014100A1 (en) 2019-01-17
US11185543B2 (en) 2021-11-30
CL2020000060A1 (es) 2020-07-31
IL271889A (en) 2020-02-27
ZA202000157B (en) 2021-08-25
AU2018301335B2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
CY1126060T1 (el) Αντιπολλαπλασιαστικες ενωσεις και διειδικο αντισωμα εναντι bcma και cd3 για συνδυασμενη χρηση
IL278854A (en) Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile
CL2019001340A1 (es) Formas cristalinas de un inhibidor de magl.
PE20191108A1 (es) Inhibidores selectivos de jak1
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
MX382150B (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
MX2022001410A (es) Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
CY1121988T1 (el) Θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
EP3735243A4 (en) ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE
IL284680A (en) Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same
MX390378B (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
MX385586B (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia.
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
IL284665A (en) Pharmaceutical compounds consisting of (S)-4- (4- (4- (((2- (2,6-dioxopyridin-3-yl)-1-oxoisoinolin-4-yl)oxy)methyl)benzyl)piperazine-1- YL)-3-fluorobenzonitrile and methods of using the same
MX2022004683A (es) Metodos de tratamiento de neoplasias hematologicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona.
EA201890585A1 (ru) Составы 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
EA202090261A1 (ru) Антипролиферативные соединения и способы их применения
AR112268A1 (es) Compuestos antiproliferativos y sus métodos de uso
BR112017012558A2 (pt) Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas
HK40051930A (en) Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
EA202090176A1 (ru) Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида
MA54460A (fr) Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine